Imatinib-d4

Imatinib-d4 (STI571-d4) is a deuterium labeled Imatinib (STI571) . Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

Product Specifications

CAS Number

[1134803-16-9]

Product Name Alternative

STI571 D4; CGP-57148B D4

UNSPSC

12352005

Hazard Statement

H361

Target

Autophagy; Bcr-Abl; c-Kit; PDGFR; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Purity

99.86

Solubility

10 mM in DMSO|DMSO : 12.5mg/mL (ultrasonic) |H2O : 10mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C4=C([2H])C([2H])=C(CN5CCN(C)CC5)C([2H])=C4[2H]

Molecular Formula

C29H27D4N7O

Molecular Weight

497.63

Precautions

H361

References & Citations

[1]Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96 (3) :925-32.|[2]Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13 (11) :3363-9.|[3]Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90 (19) :8924‐8933. Published 2016 Sep 12.